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heparin (UFH) in many patients to achieve greater clini-
cal efﬁcacy and pharmacoeconomic efﬁciency. Most hos-
pitals have not achieved clinically effective use of LMWH
and UFH in the treatment and prevention of thrombotic
disorders. The Clinical Effectiveness Initiative (CEI) was
designed to help hospitals achieve better data assessment
to measure patient outcomes, reduce medical errors,
reduce risk, and reach towards optimal ﬁnancial perfor-
mance in these patient groups. METHODS: CEI begins
with analysis of data available from the UB-92 and phar-
macy or cost-accounting systems. The actuarial analysis
provides a risk-adjusted comparison of patient cohorts
receiving antithrombotics (LMWH or UFH). Results are
reported to the institution in a format suitable for use
with performance improvement activities and physicians.
The total cost for each cohort is broken down into drug
acquisition costs and costs associated with laboratory
tests, level of care, supplies and length of stay. RESULTS:
Results completed from two hospitals in 87 DRGs that
had at least 10 discharges in each drug category (5374
LMWH, 9380 UFH) showed a case mix adjusted average
savings of $698 per discharge. The study to-date has
showed that the use of LMWH reduced overall cost in
many high-use categories, despite the higher drug acqui-
sition cost. Those included DVT, Hip and Knee replace-
ment cases. Findings also demonstrated an opportunity
for substantial savings with greater selective use of
LMWH in several cohorts that will shared in chart form.
The data analysis and structured interviews with hospital
leadership presented valuable insights into how best to
facilitate changes in practice patterns that can be contin-
ually measured. CONCLUSIONS: We conclude that the
data assessment and efﬁciency modeling capabilities of
CEI are powerful tools to help hospitals achieve clinical
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OBJECTIVES: The Japan Economic Evaluation Database
(JEED) project aims for critical appraisal of health eco-
nomic evaluation studies in Japan and build a database
with structured abstracts in collaboration with NHS-
EED. With careful preparation in 2001, we performed
handsearching of all the scientiﬁc articles and reports in
the health economic ﬁelds in Japan in 2002. We analyzed
current status of economic evaluation studies and
methodological issues. METHODS: Since January 2002,
we started to hand-search all articles and reports pub-
lished in Japanese journals. Key words for handsearching
were types of economic evaluations such as cost-
effectiveness analysis or cost-utility analysis and method-
ological terms such as utility score, willingness to pay,
QOL measurement and costing. We also adopted words
for study areas such as health economic evaluations and
pharmacoeconomics. We classiﬁed the articles into some
categories and picked up methodological issues in Japan.
RESULTS: Up to the end of September 2002, we identi-
ﬁed 223 articles and reports related to health economic
evaluations that appeared in a total of 4881 journals.
Most of the articles were general remarks or proceedings.
Thirty-four articles out of 233 were classiﬁed as original
articles, only 6 of which could be identiﬁed as full eco-
nomic evaluations. Nineteen articles were on costing and
4 were on measuring effectiveness or utility. We picked
up some issues in economic evaluation studies in Japan.
Most of the studies used reimbursement fee though there
were some studies for actual costing. Because QOL data
for health status were limited in Japanese population,
many studies adopted data from foreign countries. There
were some articles which did not use terms for economic
evaluation studies correctly. CONCLUSIONS: To
promote good economic evaluation studies in Japan, sys-
tematic critical appraisals and dissemination of informa-
tion of good studies are needed. We may have to consider
methodological guidelines or recommendations for good
economic evaluation studies.
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OBJECTIVES: Guidelines for conducting cost-utility
analyses (CUAs) contain inconsistent recommendations
for selecting cost, quality of life, and discount rate para-
meters. Sensitivity analyses can indicate whether adher-
ing to different guidelines results in different policy
recommendations. The purpose of this study is to inves-
tigate the use of sensitivity analyses to test economic 
parameters in the cost-utility literature. METHODS: Rec-
ommendations from published guidelines are summa-
rized. CUAs of pharmaceutical therapies identiﬁed in a
prior study (N = 71 articles) were reviewed and further
audited. We identiﬁed threshold CU ratios (N = 36) and
base cases for which sensitivity analyses were reported (N
= 123). For each base case, up to 2 sensitivity analyses
for cost (N = 97), quality of life (N = 136), and discount
rate (N = 127) were examined. RESULTS: There are sub-
stantial disagreements among the guidelines regarding
economic parameters. The most frequently mentioned
threshold CU ratios were $20,000/QALY, $50,000/
